Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01776424 · ClinicalTrials.gov registry record · Phase 3
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 27,395
- Enrollment target
NCT01776424 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 27,395 participants.
The verdict
NCT01776424, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27,395 participants
- Enrollment target
Study Summary
The primary objectives of this study are: * To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD); * To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.
Interventions
- DRUG Aspirin
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Aspirin placebo
- DRUG Rivaroxaban placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27,395 participants |
| Start Date | 2013-02-28 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01776424
The ClinicalTrials.gov registry entry for NCT01776424 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 27,395 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Aspirin is the first listed.
NCT01776424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01776424 about?
NCT01776424 is a clinical study titled "Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease". The primary objectives of this study are: * To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (...
What is the current status of trial NCT01776424?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27,395 participants. The study started on 2013-02-28. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT01776424?
The interventions under investigation include: Aspirin (DRUG), Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Aspirin placebo (DRUG), Rivaroxaban placebo (DRUG).
Who is sponsoring clinical trial NCT01776424?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.